**SUPPLEMENTARY DATA**

**REPRESENTATIVENES**

1. **PATIENTS**

The comparison between patients who did not undergo cognitive assessment (NC), patients who completed baseline assessment only (OBC) and patients who completed full follow-up (FFU) is shown in table 1. At baseline, all three groups were comparable with regard to clinical and functional variables. However, it must be noted that FFU patients had more years of education, better premorbid adjustment, and a lower proportion of cannabis and other drugs consumed and were more represented in higher socioeconomic groups. Additionally, 10 years after treatment initiation, they seem to have had a better clinical and functional course, showing less symptomatology as measured by BPRS, SAPS, SANS, GAF and DAS, a higher proportion of clinically stable patients and a lower proportion of institutionalized patients.

**Representativeness**

 **No cognition Only baseline cognition Full follow-up**

 **(NC) (OBC) (FFU)**

 **N M(sd) N M(sd) N M(sd) F p**

Age 83 29.80(9.18) 81 28.30(9.16) 140 29.34(8.10) 0.58 0.56

DUI (months) 80 34.76 (52.22) 81 28.84 (49.26) 136 24.06 (29.56) 1.12 0.20

DUP (months) 82 19.84 (40.92) 81 12.86 (28.16) 140 11.27 (21.39) 2.25 0.11

Education 83 9.56(3.26) 81 10.10(3.14) 140 10.83(8.10) 3.93 **0.021**

Vocabulary 75 8.47(3.03) 140 9.20(2.80) 3.17 0.08

Premorbid ad. 50 4.15(2.33) 72 3.41(2.05) 131 3.06(1.91) 5.23 **0.0062**

**BASELINE**

BPRS 83 63.06(13.14) 81 60.12(11.50) 140 61.49(12.92) 1.11 0.33

SAPS 83 13.80(4.43) 81 12.85(4.08) 140 13.05(4.36) 1.14 0.32

SANS 83 6.80(6.05) 81 6.75(6.13) 140 7.90(6.28) 1.26 0.29

DAS 54 1.46(1.45) 72 1.07(1.33) 132 1.13(1.40) 1.43 0.24

GAF 30 56.83(30.92) 27 50.48(29.45) 55 54.69(25.26) 0.38 0.68

**10 YEARS**

BPRS 33 34.21(9.15) 9 44.11(16.28) 140 30.68(7.82) 11.61 **<0.0013**

SAPS 33 2.00(2.92) 9 4.56(6.25) 140 1.31(3.05) 4.58 **0.014**

SANS 33 5.58(5.42) 9 9.56(7.02) 140 4.01(4.66) 6.16 **0.0055**

DAS 26 1.04(1.37) 4 2.5(1.73) 139 0.96(1.18) 3.42 **0.046**

GAF 26 82.12(19.45) 4 58.75(26.58) 139 83.41(16.65) 3.93 **0.027**

 **N % N % N % χ2****p**

Sex (male) 47/83 56.6% 52/81 64.2% 77/140 55.0% 1.86 0.40

Fam. History 26/82 31.7% 15/81 18.5% 30/110 27.3% 4.53 0.10

Hospitaliz. 51/83 61.4% 47/81 58.8% 94/140 97.1% 1.97 0.37

Low socioec 52/80 65.0% 49/81 60.4% 67/139 48.2% 6.72 **0.048**

**BASELINE**

With parents 43/83 51.8% 48/81 59.2% 76/140 52.3% 0.94 0.62

Single 63/83 75.9% 65/81 96.4% 106/140 75.7% 0.67 0.72

Unemployed 41/83 49.4% 38/81 46.9% 50/140 35.7% 7.70 **0.029**

**Diagnosis**  6.02 0.64

Schizophr 52/83 65.7% 44/81 54.3% 87/140 62.1%

Brief psych 8/83 9.6% 8/81 9.9% 8/140 5.7%

Unspec psych 8/83 9.6% 8/81 9.9% 8/140 5.7%

Schizophrenif. 16/83 19.3% 20/81 24.6% 34/140 24.3%

Schizoaffective 0/83 0% 1/81 1.2% 3/140 2.1%

Tobacco 51/83 61.4% 53/81 65.4% 74/140 52.8% 3.74 0.15

Cannabis 40/83 48.1% 45/81 55.5% 49/140 35.0% 9.58 **0.00810**

Other drugs 24/83 28.9% 24/81 29.6% 20/140 14.2% 9.78 **0.00811**

Alcohol 42/83 50.6% 49/80 61.2% 73/140 52.1% 2.28 0.32

**Treatment** 7.69 0.81

Aripiprazol 11/42 26.2% 12/42 28.5% 19/42 45.2%

 Risperidone 21/68 30.8% 18/68 26.4% 29/68 45.3%

 Olanzapine 13/54 24.1% 14/54 25.9% 27/54 50.0%

 Quetiapine 14/41 34.1% 9/41 21.9% 18/41 43.9%

 Ziprasidone 9/41 21.9% 9/41 21.9% 23/41 56.1%

Amisulpiride 1/1 100% 0/1 0% 0/1 0%

**10 YEARS**

**Treatment**  22.73 0.54

Aripiprazol 4/39 10.2% 5/39 12.8% 30/39 76.9%

Risperidone 5/16 31.3% 1/16 6.2% 10/16 62.5%

Olanzapine 4/21 19.0% 3/21 14.3% 14/21 66.7%

Clozapine 6/27 22.2% 2/27 7.4% 19/27 70.3%

**N % N % N % χ2****p**

Quetiapine 3/10 30.0% 2/10 20.0% 5/10 50.0%

Ziprasidone 0/5 0% 0/5 0% 5/5 100%

Risper. depot 2/8 25.0% 1/8 12.5% 5/8 62.5%

Amisulpiride 0/2 0% 0/2 0% 2/2 100%

Haloperidol 1/3 33.3% 0/3 0% 2/3 66.6%

Paliper. Depot 2/22 9.1% 4/22 18.2% 16/22 72.7%

Aripipraz. Depot 4/13 30.7% 0/13 0% 9/13 69.2%

Others 3/4 75% 0/4 0% 1/4 25%

Clinically stable 25/33 75.7% 5/9 55.5% 119/140 85.0% 5.95 **0.0512**

Func. recovery 21/33 63.6% 3/9 33.3% 96/144 68.5% 4.77 0.09

Remission 22/33 66.6% 6/9 66.6% 113/140 80.7% 3.65 0.16

**Diagnosis**  6.60 0.76

Schizophrenia 24/33 72.2% 8/9 88.8% 104/140 74.2%

Brief psychosis 2/33 6.1% 0/9 0% 4/140 2.9%

Unspec. psych. 4/33 12.2% 1/9 11.1% 8/140 5.7%

Schizophrenif 2/33 6.1% 0/9 0% 8/140 5.7%

Schizoaffective 1/33 3.0% 0/9 0% 15/140 10.7%

Delusional dis. 0/33 0% 0/9 0% 1/140 0.7%

Living parents 14/37 34.8% 12/21 57.1% 60/139 43.1% 2.08 0.35

Institutionalized 0/37 0% 2/21 9.5% 1/138 0.7% 10.14 **0.00613**

Disability 20/37 54.0% 10/21 47.6% 77/139 55.3% 0.45 0.80

Diagnostic change 27/33 81.8% 6/9 66.6% 97/140 69.3% 2.16 0.34

Unemployed 10/37 27.0% 4/21 19.0% 43/96 44.7% 1.33 0.51

1 Education: FFU over NC p=0.02

2PAS TP General: FFU over NC p=0.004

3  BPRS. All three groups improved over time (p´s<0.001). A **time by group** interaction was observed (p=0.017): BPRS 10 years; NC over OBC p= 0.008; FFU over NC P=<0.001.

4SAPS: **All three groups improved** significantly over ten years (p<0.001). At 10 years, FFU increased over OBC (p=0.01).

5SANS: Uniquely, the OBC and FFU groups improved over 10 years. A **time by group** interaction was observed (p=0.02). At 10 years, FFU increased over OBC (p=0.04

6DAS: **Longitudinally, no group improved significantly** (all ps >0.16). 10 year: FFU over OBC p=0.03**.**

7 Uniquely, NC (p=0.004) and FFC (p<0.001) improved over 10 years. GAF 10 years: NC over OBC p=0.04; FFU over OBC p=0.02

8 Low Parents sociod.: FFU over NC p=0.005.

9 Unemployment: FFU over NC p=0.001; FFU over OBC p= 0.009

10Cannabis use baseline: FFU over NC p=<0.001; FFU over OBC p= 0.02

11Other drugs baseline: FFU over NC p=0.002

12 Clinically stable at 10 years: FFU up over OBC p=0.02

13 Institutionalized at 10 years: FFU over OBC p=0.006

1. **CONTROLS**

**Representativeness**

 **No cognition (N=19) Full follow-up (N=40)**

 **M(sd)/n(%) M(sd)/n(%) T/χ2 p**

Age 26.92(5.18) 29.05(9.30) -0.93(0.36)

Education (years) 10.89(2.13) 10.64(2.60) 0.37(0.71)

Sex (male) 15(78.9) 19(47.5) 5.22(0.02)\*

Low socioeconomic

Status 7(36.8) 13(37.1) <0.001(0.98)

Cannabis (baseline) 7(36.8) 9(25) 0.85(0.36)

Drugs (baseline) 0(0) 4(19) 2.04(0.15)

**POWER OF CONTRAST AND EFFECT SIZES**

**Observed power and effect sizes in repeated series anovas**

  **Between Within TimeXGroup**

 **η p.c. η p.c. η p.c.**

Verbal Memory (Rey verbal learning test) 0.21 1 0.14 0.99 0.001 0.07

Working Memory (Backward digits) 0.14 1 0.002 0.08 0 0.55

Dexterity (Grooved pegboard) 0.10 0.99 0.02 0.42 0.008 0.29

Attention (CPTcorrects) 0.06 0.87 0.008 0.15 0.008 0.26

Visual memory (Rey complex figure) 0.13 0.99 0.23 1 0.04 0.91

Speed of processing (Digit symbol) 0.29 1 0.29 1 0.002 0.11

Executive functions (TMTB) 0.14 0.99 0.03 0.57 0.004 0.16

Global cognition 0.13 0.99 0.20 1 0.006 0.20

**η= Effect size**

**p.c.= Observed power**